Genetic Technologies Limited (GENE)
| Market Cap | 14.01M |
| Revenue (ttm) | 5.99M |
| Net Income (ttm) | -8.10M |
| Shares Out | 5.84M |
| EPS (ttm) | -4.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,980 |
| Open | 2.50 |
| Previous Close | 2.43 |
| Day's Range | 2.32 - 2.50 |
| 52-Week Range | 2.12 - 12.00 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 13, 2024 |
About GENE
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as ... [Read more]
Financial Performance
In 2023, GENE's revenue was 8.69 million, an increase of 27.83% compared to the previous year's 6.79 million. Losses were -11.75 million, 64.8% more than in 2022.
Financial numbers in AUD Financial StatementsNews
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Mone...
Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change
MELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious...
GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment
MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious...
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDA...
GTG Signs Precision Medicine Pilot with Australia's Largest Private Hospital Network
MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serio...
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE), and American Re...
GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice
Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV
MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, we...
Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money R...
Annual Results – Momentum Building on our Commercial Plans
MELBOURNE, Australia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wel...
Cardio Diagnostics Partners With FRSTeam of East Kansas and West Missouri to Host First Onsite Heart Disease Fair in Kansas Using Epigenetic-Genetic Technologies
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the successful completion of an employer-sponsored heart disease fair in Kansas, United States.
Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness and serious disease, advises ...
New Publication Validates geneType for Melanoma Risk Assessment
MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious...
Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and seriou...
Genetic Technologies Announces Closing of $5 Million Registered Direct Offering
MELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-b...
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious...
Genetic Technologies Announces $5 Million Registered Direct Offering
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-b...
GENE to Launch World's First Comprehensive Risk Test for Breast & Ovarian Cancer
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious ...
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health, wellne...
GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wel...
Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details
MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wel...
Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / October 13, 2022 / RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based ...
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer
MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and seriou...
Genetic Technologies Provides Update on US Operations and Payer Engagement
MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in he...
GENE Momentum building - a year in review
MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health, we...